Thornburg Investment Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $541M | Buy |
2,891,426
+32,775
| +1% | +$6.16M | 5.17% | 6 |
|
|
2026
Q1 | $556M | Buy |
2,858,651
+2,605,658
| +1,030% | +$502M | 5.77% | 5 |
|
|
2025
Q4 | $46.5M | Sell |
252,993
-2,481
| -1% | -$435K | 0.59% | 33 |
|
|
2025
Q3 | $39.2M | Sell |
255,474
-12,351
| -5% | -$1.87M | 0.51% | 36 |
|
|
2025
Q2 | $37.4M | Buy |
267,825
+9,281
| +4% | +$1.3M | 0.48% | 39 |
|
|
2025
Q1 | $380M | Buy |
258,544
+5,783
| +2% | +$837K | 0.53% | 38 |
|
|
2024
Q4 | $33.1M | Buy |
252,761
+9,748
| +4% | +$1.36M | 0.44% | 44 |
|
|
2024
Q3 | $37.9M | Sell |
243,013
-2,722
| -1% | -$439K | 0.49% | 45 |
|
|
2024
Q2 | $38.3M | Sell |
245,735
-4,879
| -2% | -$734K | 0.54% | 41 |
|
|
2024
Q1 | $34M | Sell |
250,614
-3,822
| -2% | -$506K | 0.47% | 42 |
|
|
2023
Q4 | $34.4M | Sell |
254,436
-31,604
| -11% | -$4.11M | 0.5% | 43 |
|
|
2023
Q3 | $38.7M | Sell |
286,040
-4,138
| -1% | -$565K | 0.64% | 37 |
|
|
2023
Q2 | $41.5M | Sell |
290,178
-53,201
| -15% | -$7.83M | 0.67% | 36 |
|
|
2023
Q1 | $47.7M | Sell |
343,379
-21,837
| -6% | -$2.94M | 0.79% | 33 |
|
|
2022
Q4 | $49.7M | Sell |
365,216
-64,220
| -15% | -$8.05M | 0.84% | 27 |
|
|
2022
Q3 | $47.1M | Buy |
429,436
+26,761
| +7% | +$3.39M | 0.83% | 28 |
|
|
2022
Q2 | $53.2M | Sell |
402,675
-78,140
| -16% | -$10.3M | 0.81% | 28 |
|
|
2022
Q1 | $63.8M | Sell |
480,815
-49,632
| -9% | -$5.95M | 0.84% | 28 |
|
|
2021
Q4 | $61.8M | Buy |
530,447
+47,685
| +10% | +$5.61M | 0.72% | 32 |
|
|
2021
Q3 | $58M | Buy |
482,762
+2,299
| +0.5% | +$268K | 0.71% | 35 |
|
|
2021
Q2 | $57.6M | Buy |
480,463
+42,366
| +10% | +$4.65M | 0.66% | 39 |
|
|
2021
Q1 | $43.6M | Buy |
438,097
+61,100
| +16% | +$6.14M | 0.51% | 48 |
|
|
2020
Q4 | $37.7M | Sell |
376,997
-2,142
| -0.6% | -$227K | 0.45% | 52 |
|
|
2020
Q3 | $41.6M | Sell |
379,139
-1,932
| -0.5% | -$215K | 0.55% | 56 |
|
|
2020
Q2 | $40.3M | Sell |
381,071
-7,469
| -2% | -$771K | 0.52% | 56 |
|
|
2020
Q1 | $34.7M | Buy |
388,540
+6,927
| +2% | +$652K | 0.5% | 55 |
|
|
2019
Q4 | $38.1M | Sell |
381,613
-13,074
| -3% | -$1.23M | 0.37% | 65 |
|
|
2019
Q3 | $35.2M | Sell |
394,687
-5,155
| -1% | -$447K | 0.34% | 68 |
|
|
2019
Q2 | $33M | Buy |
399,842
+46,311
| +13% | +$3.63M | 0.32% | 75 |
|
|
2019
Q1 | $28.6M | Buy |
353,531
+26,391
| +8% | +$2.08M | 0.28% | 80 |
|
|
2018
Q4 | $24.9M | Sell |
327,140
-3,447
| -1% | -$269K | 0.24% | 81 |
|
|
2018
Q3 | $26.2M | Buy |
330,587
+37,083
| +13% | +$2.8M | 0.22% | 86 |
|
|
2018
Q2 | $20.6M | Buy |
293,504
+76,892
| +35% | +$5.53M | 0.16% | 127 |
|
|
2018
Q1 | $15.2M | Buy |
+216,612
| New | +$15M | 0.11% | 142 |
|
Other funds holding AZN
EP
IA
Thornburg Investment Management's AZN Position: Q2 2026 in Review
Thornburg Investment Management increased its AstraZeneca (AZN) stake by 1.1% in Q2 2026, buying an estimated $6.16M and bringing the position to 2,891,426 shares worth $541M. The position accounts for 5.17% of the portfolio, ranked #6.
Thornburg Investment Management first reported a position in AZN in Q1 2018 and has held it in 34 quarters since. The position peaked at $556M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Thornburg Investment Management held 2,891,426 shares of AstraZeneca worth $541M as of Q2 2026.
- Thornburg Investment Management bought 32,775 AstraZeneca shares in Q2 2026, an estimated $6.16M.
- AstraZeneca made up 5.17% of Thornburg Investment Management's portfolio in Q2 2026, its #6 holding.
- Thornburg Investment Management first reported a position in AstraZeneca in Q1 2018 and has held it in 34 quarters since.
- Thornburg Investment Management's AstraZeneca position peaked at $556M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Thornburg Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.